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Free radicalsMitochondrial dysfunction and oxidative stress are hallmarks of various neurological disorders, including
multiple sclerosis (MS), Alzheimer disease (AD), and Parkinson disease (PD). Mutations in PINK1, a
mitochondrial kinase, have been linked to the occurrence of early onset parkinsonism. Currently, various
studies support the notion of a neuroprotective role for PINK1, as it protects cells from stress-mediated
mitochondrial dysfunction, oxidative stress, and apoptosis. Because information about the distribution
pattern of PINK1 in neurological diseases other than PD is scarce, we here investigated PINK1 expression in
well-characterized brain samples derived from MS and AD individuals using immunohistochemistry. In
control gray matter PINK1 immunoreactivity was observed in neurons, particularly neurons in layers IV–VI.
Astrocytes were the most prominent cell type decorated by anti-PINK1 antibody in the white matter. In
addition, PINK1 staining was observed in the cerebrovasculature. In AD, PINK1 was found to colocalize with
classic senile plaques and vascular amyloid depositions, as well as reactive astrocytes associated with the
characteristic AD lesions. Interestingly, PINK1was absent from neuroﬁbrillary tangles. In active demyelinating
MS lesions we observed a marked astrocytic PINK1 immunostaining, whereas astrocytes in chronic lesions
were weakly stained. Taken together, we observed PINK1 immunostaining in both AD and MS lesions,
predominantly in reactive astrocytes associated with these lesions, suggesting that the increase in astrocytic
PINK1 protein might be an intrinsic protective mechanism to limit cellular injury.ell Biology and Immunology,
l Center, 1007MB Amsterdam,
en).
 OA license.© 2010 Elsevier Inc. Open access under the Elsevier OA license.Although Parkinson disease (PD) classically presents in a sporadic
fashion, the discovery of pathogenetic mutations in inherited PD
genes has provided crucial insight into the pathogenesis of this
neurodegenerative disorder [1]. The ﬁrst mutations were found in the
SNCA gene, which encodes the α-synuclein protein that is deposited
in the classical pathological lesions of PD, the Lewy bodies, and led to
autosomal dominant forms of PD [2]. Later on, mutations in the PARK2
gene, which encodes the parkin protein, were reported [3], followed
by mutations in DJ-1 [4] and PTEN-induced putative kinase (PINK1)
[5], found in autosomal recessive parkinsonism. The PINK1 gene codes
for a highly conserved 581-amino-acid protein with a catalytic serine/
threonine kinase domain. Importantly, the identiﬁcation of PD-
associated genes and their protein products has signiﬁcantlyincreased our understanding regarding the biological functions of
parkin, PINK1, and DJ-1 [6].
PINK1 is a mitochondrially targeted kinase and is ubiquitously
expressed throughout the adult body with the highest levels of mRNA
expression in skeletal muscle, testis, and heart [7]. Furthermore, the
PINK1 protein is abundantly expressed in the human central nervous
system (CNS), especially in neurons and glial cells in both gray and
white matter tissue [8]. Although the precise function of PINK1 is not
fully understood, it has been reported that PINK1 protects cells from
stress-induced mitochondrial dysfunction, oxidative stress, and
apoptosis [9]. Interestingly, knockout of parkin, an E3 ubiquitin ligase
linked to recessive juvenile parkinsonism [3–10], and PINK1 results in
mitochondrial abnormalities. Furthermore, parkin can rescue the loss
of PINK1, indicating that both proteins operate in the same genetic
network [11]. Knockdown of PINK1 in human neurons and neuronal
cell lines resulted in extensive mitochondrial dysfunction, enhanced
reactive oxygen species (ROS) formation, and reduced neuronal cell
viability, demonstrating the neuroprotective properties of PINK1 [12].
PINK1 is also involved in the regulation of mitochondrial calcium
efﬂux, as PINK1 deﬁciency led to increased mitochondrial calcium
Table 1
AD patient characteristics
Patient Diagnosis Gender Age PMI
(h)
Grade
(Braak, NFT)
Grade
(Braak, Aβ)
Grade CAA
1 Control M 90 6 1 B/C −
2 Control F 61 7 0 O −
3 Control M 96 7 1 O −
4 Control M 50 7 ND ND −
5 Control M 57 6 1 O −
6 AD F 66 ND 6 C −
7 AD F 68 4 6 C −
8 AD M 87 6 5 C −
9 AD F 84 7 5 C −
10 AD M 82 10 4 C −
11 AD/CAA F 75 6 5 C +++
12 AD/CAA F 91 7 5 C ++
13 AD/CAA M 75 5 4 C ++
14 AD/CAA F 70 4 6 C +++
15 AD/CAA M 65 6 6 B ++
AD, Alzheimer disease; CAA, cerebral amyloid angiopathy; F, female; M, male; PMI,
postmortem interval; ND, not determined; NFT, neuroﬁbrillary tangles; Aβ, amyloid-β.
Grading of AD (Braak) and of CAA was performed as described under Materials and
methods.
Table 2
MS patient characteristics
Patient Gender Age PMI
(h)
Disease type Disease duration
(years)
Type of lesion
1 M 47 7 SP 7 CIA (2×)
2 F 69 13 SP 27 CIA
3 F 45 11 SP 31 A
4 M 41 7 PP 14 A, CIA
5 F 72 6 SP 13 A
6 F 66 6 SP 23 A
7 M 59 22 SP 32 A
MS, multiple sclerosis; F, female; M, male; PMI, postmortem interval; SP, secondary
progressive; PP, primary progressive; ND, not determined; A, active lesion; CIA, chronic
inactive lesion. Classiﬁcation of MS lesion type was performed as described under
Materials and methods.
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generation [13]. Although evidence is emerging that PINK1 exerts
neuroprotective properties, remarkably little is known about the
cellular distribution and involvement of PINK1 in other neurological
disorders than PD, such as multiple sclerosis (MS) and Alzheimer
disease (AD).
Alzheimer disease is a progressive neurodegenerative brain disease
and the most common form of dementia. Although the cause and
progression of AD are not well understood, histopathological analysis
reveals the presence of abnormal protein aggregates throughout the
cortex and some subcortical regions. The main pathological lesions
observed in AD-affected brain tissue are senile plaques (SPs), which
comprise aberrantdeposits of aggregatedamyloid-βprotein (Aβ)protein
in the brain parenchyma; cerebral amyloid angiopathy (CAA), which is
characterized by accumulation of aggregated Aβ deposition in the
cerebrovasculature; and neuroﬁbrillary tangles (NFTs), intraneuronal
deposits of hyperphosphorylated tau protein [14]. In the past decade
substantial progress has been made in the elucidation of mechanisms
underlying ADpathogenesis and there is a growing body of evidence that
points toward the involvement of mitochondrial dysfunction and
increased free radical production in AD pathology [15–19]. Likewise,
impaired mitochondrial dysfunction and concomitant oxidative injury
have been implicated in the neuroinﬂammatory disorder multiple
sclerosis [20–23]. MS is a chronic inﬂammatory and demyelinating
disease of the CNS particularly affecting young adults. MS patients may
suffer from a wide variety of clinical symptoms, including changes in
sensation, visual problems, muscle weakness, and difﬁculties with
coordination and speech [24]. Common pathological features of MS are
white matter plaques, which demonstrate disturbed blood–brain barrier
integrity, destruction of myelin sheaths, oligodendrocyte damage, and
cell death; axonal damage and axonal loss; glial scar formation; and the
presence of inﬂammatory inﬁltrates that generally consist of lympho-
cytes and macrophages [25]. Like AD, despite major advances in recent
years, the etiology of this devastating disease is still not completely
understood.
Although the pathogenetic mechanisms underlying AD andMS are
diverse, mitochondrial dysfunction, impaired calcium metabolism,
and oxidative stress are commondenominators in both diseases. Given
PINK1's mode of action in mitochondrial maintenance and neuropro-
tection, it is likely that PINK1 is also involved in promoting neuronal
survival in other neurological diseases than PD. Remarkably, data on
the distribution of PINK1 protein in AD brain tissue are scarce, whereas
studies on PINK1 expression in MS lesions are lacking. To gain insight
into the distribution of PINK1 in AD and MS brain, and possible
colocalization of PINK1 with the characteristic brain lesions in both
diseases, we used immunohistochemistry on well-characterized
human brain tissue of AD and MS patients.
Materials and methods
Brain tissue
Temporal neocortex tissue samples from 10 AD patients (age
71.3±9.2 years; postmortem delay 6.1±1.8 h), 5 AD patients with
CAA, and 5 control subjects without neurological disease (age 71±
21 years; postmortem delay 6.6±0.5 h) were obtained after rapid
autopsy and immediately frozen in liquid nitrogen (in collaboration
with The Netherlands Brain Bank, Amsterdam, coordinator Dr. I.
Huitinga; Table 1). In addition, we collected nine lesions from 7
patients with clinically diagnosed and neuropathologically con-
ﬁrmed MS (Table 2). The Netherlands Brain Bank received
permission to perform autopsies, for the use of tissue, and for access
to medical records for research purposes from the Ethics Committee
of the VU University Medical Center (Amsterdam, The Netherlands).
The diagnosis of AD was based on a combination of neuropath-
ological and clinical criteria [26]. Table 1 provides an overview of thediagnosis, Braak & Braak score, CAA grading, age, postmortem
interval, and gender of the AD patients used in this study. CAA
grading was established by quantiﬁcation of the number of Aβ-
positive vessels in one microscopic ﬁeld (magniﬁcation 2.5×), as
described in a previous report [27]. At least four microscopic ﬁelds of
temporal neocortex were analyzed and categorized as follows: 0 (−,
no CAA), 0–10 (+, sparse CAA), 10–20 (++, moderate CAA), and N20
(+++, severe CAA) vessels affected by Aβ deposition.
MS tissue sampleswere selectedon thebasis ofpostmortemMRIand
lesions were classiﬁed according to standard histopathological criteria
aspreviously published [28]. Relevant clinical informationwas retrieved
from themedical records and is summarized in Table 2. All patients and
controls, or their next of kin, had given informed consent for autopsy
and use of their brain tissue for research purposes. MS lesions were
detected and classiﬁed by immunohistochemical analysis using anti-
bodies directed against proteolipid protein, a myelin component, and
anti-major histocompatibility complex class II, clone LN3, as described
previously [29,30]. In short, active lesions are characterized by loss of
myelin and abundant perivascular and parenchymal leukocyte inﬁltra-
tion. In some cases, inﬁltratedmacrophages containmyelin degradation
products. Chronic inactive lesions are hypocellular and contain few
inﬂammatory cells. Based on the myelin and MHC class II stainings we
identiﬁed ﬁve active lesions and four chronic inactive lesions.
Immunohistochemistry
Immunohistochemistry was used to detect PINK1 immunostaining
in temporal neocortex and white matter in AD, MS, and control
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10 min. Next, sections were incubated with an afﬁnity-puriﬁed rabbit
anti-PINK1 antibody (1:100; Neuromics, Edina, MN, USA) for 60 min
at room temperature. Then, the slides were incubated with EnVision
kit horseradish peroxidase-labeled anti-mouse/rabbit (DAKO,
Glostrup, Denmark) for 30 min at room temperature and ﬁnally
diaminobenzidine tetrachloride. Between incubation steps, sections
were thoroughly washed with phosphate-buffered saline (PBS). After
a short rinse in tap water sections were incubated with hematoxylin
for 1 min and extensively washed with tap water for 10 min. Finally,
sections were dehydrated with ethanol followed by xylol and
mounted with Entellan (Merck, Darmstadt, Germany). All antibodies
were diluted in PBS containing 0.1% bovine serum albumin (Boehrin-
ger–Mannheim, Germany), which also served as a negative control.
Negative controls were essentially blank. Congo red staining of AD
tissue was performed as described in a previous report [26]. Sections
were analyzed using a Leica DM6000 B digital microscope (Leica
Microsystems, Rijswijk, The Netherlands).Double immunoﬂuorescence
For colocalization studies, sections were incubated for 60 min at
room temperature with anti-PINK1 antibody together with an
antibody directed against glial ﬁbrillary acidic protein (Z0334, GFAP;
1:500; DAKO), major histocompatibility complex (MHC) class II
(1:50; DAKO), Aβ (ab 10148, 1:400; Abcam, Cambridge, UK), or
hyperphosphorylated tau (AT8, 1:1000; Thermoscientiﬁc, Rockford,
IL, USA). Sections were simultaneously incubated with the primaryFig. 1. Immunohistochemical staining of PINK1 in the neocortex and white matter of contr
localized in neocortical neurons (black line indicates the border between cortex and white m
and blood vessels (arrowhead). Original magniﬁcation: (A) 20×, (B) 200×, (C) 100×.antibodies of interest. Biotin-labeled goat anti-mouse antibody
coupled to Alexa-594 (1:400; Molecular Probes, Eugene, OR, USA)
or biotin-labeled donkey anti-rabbit antibody coupled to Alexa-488
(1:400; Molecular Probes) was used as secondary antibody. Between
all incubation steps, sections were extensively washed in PBS (pH
7.4). Sections were analyzed using a Leica TCS SP2 AOBS confocal laser
scanning microscope (Leica Microsystems).
Results
PINK1 distribution in neocortex and white matter of control brain tissue
PINK1 immunoreactivity was predominantly observed in neuronal
cell bodies (Figs. 1A and B), particularly in layers IV–VI. Furthermore,
PINK1 staining showed a diffuse parenchymal staining pattern through-
out the neocortex (Figs. 1A and B). In the white matter, the anti-PINK1
antibody mainly decorated cells with an astrocyte-like appearance
(Fig. 1C). PINK1 immunostaining was also found in endothelial and
smooth muscle cells of both leptomeningeal vessels and a number of
larger parenchymal vessels in white and grey matter (Fig. 1C).
PINK1 distribution in AD brain
In AD brains, the general staining pattern of PINK1was similar to that
of control brain. However, the anti-PINK1 antibody sporadically demon-
strated colocalizationwith theAβpart of classic SPs (Figs. 2A–C),whereas
noPINK1 immunoreactivitywasobserved in either diffuse SPs anddiffuse
Aβ deposition surrounding vessels (data not shown). In addition,ol brain. (A, B) PINK1 is diffusely expressed throughout the cortex and predominantly
atter). (C) In the white matter PINK1 was associated with astrocyte-like cells (arrow)
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colocalization of anti-PINK1 immunoreactivity was observed with
hyperphosphorylated tau protein in NFTs (Figs. 2D–F). Interestingly
however, CAA in AD brain displayed marked anti-PINK1 staining
(Figs. 2G–I). Furthermore, PINK1 immunostaining was observed in
reactive astrocytes, conﬁrmed with GFAP immunostaining, associated
with the aforementioned AD lesions and throughout the affected
neocortex of AD patients (Figs. 2J–L).Fig. 2. Double immunoﬂuorescence staining of PINK1 with Aβ in SPs and CAA and with hype
in an occasional classic SP. (D–F) Although PINK1 staining was observed in norma
hyperphosphorylated tau in NFTs (arrows). (G–I) PINK1 staining strongly colocalized with
reactive astrocytes (GFAP) throughout the affected neocortex of AD patients (arrows). Origin
plaque; NFTs, neuroﬁbrillary tangles; CAA, cerebral amyloid angiopathy; AD, Alzheimer disPINK1 distribution in MS brain
Active MS lesions are characterized by widespread loss of myelin
(Fig. 3A) and abundant inﬂammatory cells (Fig. 3B). In active
demyelinating MS lesions we observed enhanced expression of
PINK1 in astrocyte-like cells (Fig. 3C). Double staining with the
astrocytic marker GFAP conﬁrmed increased immunoreactivity of
PINK1 in reactive astrocytes in active MS lesions (Fig. 3C, inset).rphosphorylated tau in NFTs. (A–C) Anti-PINK1 antibody immunoreactivity was present
l neurons (arrows with asterisk), no PINK1 immunoreactivity colocalized with
Aβ in CAA and (J–L) demonstrated colocalization with an antibody directed against
al magniﬁcation: (A–F, J–L) 250×, (G–I) 200×. Abbreviations: Aβ, amyloid-β; SP, senile
ease; GFAP, glial ﬁbrillary acidic protein.
Fig. 3. Immunohistochemical staining of PINK1 in active and chronic inactive MS lesions. Active MS lesions are characterized by (A) loss of myelin and (B) abundant MHC class II-
positive leukocytes. (C) In active lesions PINK1 immunostaining was intense in reactive astrocytes (arrows). Double labeling of PINK1 (green) with the astrocytic marker GFAP (red)
demonstrated PINK1 expression in astrocytes (inset). (D–F) PINK1 (D) was virtually absent in inﬁltrated MHC class II-positive leukocytes (E, F), but strongly stained astrocytic cells
(D, F). (G) PINK1 immunoreactivity showed a diffuse staining pattern in chronic inactive MS lesions. Original magniﬁcation: (A, B) 20×, (C–G) 200×.
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PINK1 immunoreactivity in inﬁltrated leukocytes in active lesions
(Figs. 3D–F). In chronic inactive lesions PINK1 staining showed aweak
diffuse parenchymal staining pattern (Fig. 3G). Moreover, in contrast
to active lesions, astrocytes in chronic inactive lesions were only
weakly PINK1 immunopositive (Fig. 3G).Discussion
Here, for the ﬁrst time we demonstrate the association of PINK1
with the characteristic brain lesions of both AD andMS. In AD brains, a
strong PINK1 immunostaining was observed in reactive astrocytes
associated with the characteristic lesions, in particular SPs and CAA, of
AD and in the affected brain areas. Until now, PINK1 distribution
studies in brain have been limited to both normal and PD brain. In
normal brain, PINK1 is observed in endothelial cells and smooth
muscle cells of blood vessels, in neuronal cell bodies, and in astrocytes
[8]. Our ﬁndings of PINK1 distribution in normal brain are in line with
these data. Moreover, in PD brain, a similar distribution pattern of
PINK1 is observed in comparison with normal tissue [8]. However, in
neuromelanin-containing neurons of the substantia nigra, a typical
granular staining pattern of PINK1 is observed. In addition, 5–10% of
all α-synuclein-containing Lewy bodies in the brain stem are positive
for PINK1 [8]. Surprisingly, although PINK1 has been described only
intracellularly, we found PINK1 staining in the extracellular aggre-
gated Aβ core of classic SPs and in CAA-affected vessels. Furthermore,
although PINK1 immunostaining was observed in normal neurons, no
colocalization was found with the intracellular hyperphosphorylated
tau inclusions in NFTs. In MS, marked astrocytic PINK1 immunostain-
ing was observed associated with active demyelinating MS lesions,
whereas astrocytes in chronic lesions were only weakly stained.
Although the exact role of PINK1 in reactive astrocytes in AD brain and
MS lesions remains to be elucidated, PINK1 is suggested to protect
cells from stress-mediated mitochondrial dysfunction, oxidative
stress, and apoptosis. In addition, both the mechanisms underlying
the presence of PINK1 in the extracellular space in AD and its possible
function outside the cells need to be addressed in future studies.
Our data suggest a possible role for PINK1 in AD pathogenesis,
because we observed colocalization of PINK1 with aggregated Aβ
deposits in both classic SPs and CAA. These ﬁndings are interesting,
because PINK1 is reported only as an intracellular protein so far. In
brain, Aβ is produced by neurons and transported toward the cerebral
vessels via the interstitial ﬂuid drainage [31]. This results in increasing
levels of Aβ taken up by the (peri)vascular cells [32] and subsequent
formation of toxic free radicals [33]. This process might be counter-
acted by activating or upregulation of PINK1 as a means of protecting
cerebrovascular cells against cell injury. However, whether PINK1 is
secreted by these cerebrovascular cells in CAA or PINK1 appears
extracellularly though Aβ-mediated cell leakage or cell death in the
pathogenesis of CAA is unclear. In addition, the absence of PINK1 from
diffuse SPs indicates that PINK1 might be more associated with
ﬁbrillar Aβ, characteristic of classic SPs and CAA, than nonﬁbrillar Aβ,
as found in diffuse SPs. Finally, PINK1 immunoreactivity was
abundantly present in reactive astrocytes associated with SPs and
CAA and throughout the affected brain areas in AD. This points toward
an increase in PINK1 expression in these astrocytes, compared to
control brain. In AD, reactive astrocytes are known to take up and
degrade Aβ in an attempt to clear Aβ from the brain [34]. However,
this uptake of Aβ by glial cells results in oxidative stress and elevated
ROS production [35]. As an attempt to counteract this Aβ-induced
oxidative stress, PINK1 might be upregulated in these reactive
astrocytes in AD. Thus, considering PINK1's alleged involvement in
protective cellular mechanisms, it is likely that PINK1 protects
reactive astrocytes from the Aβ-mediated cell damage that is induced
by its internalization.Inﬂammation is of prime importance in the cellular damage
observed in MS [24,25]. Inﬁltrated immune cells produce nitric oxide
and reactive oxygen species, which are known to cause oxidative
stress and cellular injury [22,23]. Here, we showed enhanced
astrocytic PINK1 immunoreactivity in active MS lesions. In contrast,
we observed weak astrocytic PINK1 immunostaining in chronic
inactive lesions. In fact, our data suggest that during the chronic
phase of the disease, when inﬂammation has abated, PINK1 levels
revert to those observed in control white matter.
PINK1 and parkin function in the same cell survival pathway, with
PINK1 functioning upstream of parkin [36–38]. Recently, Matsuda and
colleagues demonstrated that PINK1 recruits parkin from the
cytoplasm to damaged mitochondria, thereby protecting the mito-
chondria and thus contributing to cell survival [39]. Our study
demonstrated increased PINK1 immunoreactivity in astrocytes asso-
ciated with the pathological lesions of both AD and MS, which is in
line with our previous report that showed augmented parkin
immunoreactivity in astrocytes associated with SPs and CAA in AD
and in both chronic and active MS lesions [40]. The elevated
immunoreactivity of both PINK1 and parkin in reactive astrocytes
associated with AD and MS pathology indicates mitochondrial stress
in these cells. In vitro studies already demonstrated that parkin
expression is upregulated upon oxidative stress [40] and over-
expression of parkin protects cells from (oxidative) stress and targets
misfolded proteins for proteasomal degradation. Notably, overexpres-
sion of PINK1 signiﬁcantly reduced the susceptibility to neurotoxin-
induced cell death [41]. Thus, upon oxidative stress and cellular
damage induced by the pathological processes underlying AD andMS,
astrocytes may upregulate the production of PINK1, which recruits
parkin to the stressed mitochondria. Surprisingly, however, we and
others found no PINK1 immunoreactivity in NFTs in AD, although
normal neurons did demonstrate the presence of PINK1 [7]. This
absence of PINK1 from NFTs might explain our previous ﬁndings that
parkin also was not observed in NFTs, in contrast to unaffected
neurons [40]. This is surprising, because both oxidative stress and
consequently mitochondrial dysfunction are well-known features in
AD pathogenesis [42]. However, a considerable body of evidence is
growing suggesting that the oxidative stress in neurons might also be
counteracted by tau itself, because oxidative damage is reduced in
neurons demonstrating cytopathology [42]. Therefore, the absence of
both PINK1 and parkin from NFTs might suggest that these neurons
are protected against mitochondrial damage via a tau-driven
mechanism, rather than through PINK1 and parkin. Finally, alterations
in PINK1 expression, as a consequence of cell stress or other factors,
might also be indicative of PINK1's role in maintenance of mitochon-
drial functioning, as PINK1 deletion induces alterations in mitochon-
drial morphology. Consequently, these alterations were shown to be
directly related to apoptosis [37,38,43]. Alternatively, PINK1 levels in
cells might also be related to calcium signaling, because PINK1
deﬁciency induces a higher vulnerability to calcium-induced loss of
ΔΨm and subsequently permeability transition pore opening [13].
Additionally, increased production of ROS was observed secondary to
mitochondrial calcium overload [13], which might serve as a negative
feedback loop.
Astrocytes are known to play diverse roles in neurological
diseases. For instance, they are able to produce proinﬂammatory
mediators [44] and hamper myelin repair [45]. Conversely, astrocytes
are able to suppress inﬂammation, buffer extracellular glutamate [46],
and produce high levels of antioxidant enzymes [23,29,47–49]. It is
likely that in inﬂammatory MS lesions as well as in SPs and CAA in AD,
astrocytes become reactive because of changes in the inﬂammatory
microenvironment. Collectively, we showed that under pathological
conditions astrocytes produce a vast array of neuroprotective
proteins, such as parkin, DJ-1, and PINK1 to protect themselves and
the surrounding tissue against cell stress of various natures, including
ROS and proinﬂammatory mediators [29,40].
475M.M.M. Wilhelmus et al. / Free Radical Biology & Medicine 50 (2011) 469–476Taken together, we observed abundant PINK1 immunoreactivity
associated with characteristic AD and MS lesions. PINK1 colocalizes
with classic SPs and vascular amyloid in AD tissue as well as astrocytes
associated with these lesions. Similarly, astrocytic PINK1 immuno-
reactivity was prominent in demyelinating MS lesions. Because it has
been demonstrated that PINK1 exerts protective properties by
limiting mitochondrial and oxidative stress, we hypothesize that
increased PINK1 expression represents an intrinsic defense mecha-
nism to counteract cellular injury. Additional studies are needed to
reveal PINK1's role in the pathogenesis of neurodegenerative and
neuroinﬂammatory diseases such as AD and MS. Such studies will
provide important clues as to whether PINK1 expression and/or
activity might represent a therapeutic target to promote cell survival
in these devastating neurological disorders.
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